China Pharma Holdings, Inc. CPHI
0.75
0.01
1.35%
as of 25 Sep
- Market cap
- $31.8M
- P/E
- 0.0×
Follow CPHI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(42.98%) | (20.91%) | (16.12%) | (20.99%) | |
| (21.80%) | (13.89%) | (11.94%) | (15.30%) | ||
ROIC |
(20.27%) | (8.31%) | (5.80%) | (7.23%) | |
Return on Tangible Assets |
(1,525.54%) | 481.51% | 369.24% | 307.50% | |
Average Days of Receivables |
25.75 | 25.60 | 23.58 | 23.15 | |
Free Cash Flow per Share |
(0.04) | (0.01) | 0.01 | 0.00 | |
Free Cash Flow |
(0.16) | (0.04) | 0.17 | (0.14) | |
Capital Expenditures |
(0.46) | (0.19) | — | — | |
Piotroski F-Score |
5.00 | 5.00 | 5.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
2.79% | 0.59% | 0.43% | (0.37%) | |
Accounts Receivable Turnover |
12.17 | 14.99 | 12.76 | 13.85 | |
Accounts Payable Turnover |
9.19 | 7.66 | 5.34 | 5.46 | |
Inventory Turnover |
2.17 | 2.20 | 2.13 | 2.27 | |
Average Days of Payables |
47.80 | 76.06 | 82.54 | 77.57 | |
Days of Inventory on Hand |
133.94 | 138.40 | 147.75 | 143.98 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2.26% | 6.78% | 8.40% | 8.51% | |
Selling, General and Administrative Expense of Revenue |
65.97% | 68.22% | 89.06% | 115.06% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.09) | (0.05) | (0.05) | 0.03 | |
Depreciation/Fixed assets |
0.34 | 0.36 | 0.52 | 0.72 | |
Capex/Depreciation |
(0.30) | (0.12) | 0.00 | 0.00 | |
Revenue per Share |
1.05 | 0.97 | 0.16 | 0.10 | |
Operating CF per Share |
0.08 | 0.03 | 0.01 | 0.00 | |
Capex per Share |
(0.12) | (0.04) | 0.00 | 0.00 | |
Capex to Sales |
0.11 | 0.05 | 0.00 | 0.00 | |
Net Profit Margin |
(78.72%) | (76.92%) | (88.82%) | (114.33%) |
Columns are period end dates